{"url_path":"/sec/ipsc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059816-index.html","accession_number":"0001104659-26-059816","cik":"0001850119","ticker":"IPSC","issuer_name":"Century Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059816-index.html","primary_entity_key":"0001850119","primary_entity_name":"Century Therapeutics, Inc."},"word_count":636,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n​\n\n​\n\n​\n\n**Exhibit**\n\n**Number**\n\n  ​ ​ ​\n\n​\n\n​\n\n​\n\n4.1\n\n​\n\n[Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K (File No. 001-40498) filed on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_ex4-1.htm)\n\n4.2\n\n​\n\n[Form of Common Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K (File No. 001-40498) filed on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_ex4-2.htm)\n\n10.1\n\n​\n\n[Securities Purchase Agreement, dated January 7, 2026, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K (File No. 001-40498) filed on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_ex10-1.htm)\n\n10.2\n\n​\n\n[Registration Rights Agreement, dated January 7, 2026, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K (File No. 001-40498) filed on January 8, 2026).](https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_ex10-2.htm)\n\n10.3**\n\n​\n\n[First Amendment to the Catalent License Agreement for Use of Catalent IPSC Lines in Pre-Clinical and Clinical Development, and Commercialisation of Cell Therapies, dated March 25, 2026 by and between the Company and Catalent](ipsc-20260331xex10d3.htm)\n\n31.1\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ipsc-20260331xex31d1.htm)\n\n31.2\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ipsc-20260331xex31d2.htm)\n\n32.1*\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ipsc-20260331xex32d1.htm)\n\n32.2*\n\n​\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ipsc-20260331xex32d2.htm)\n\n101.INS\n\nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema\n\n101.CAL\n\nInline XBRL Taxonomy Extension Calculation Linkbase\n\n101.DEF\n\nInline XBRL Taxonomy Extension Definition Linkbase\n\n101.LAB\n\nInline XBRL Taxonomy Extension Label Linkbase\n\n101.PRE\n\nInline XBRL Taxonomy Extension Presentation Linkbase\n\n104\n\n​\n\nThe cover page from Century Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL and contained in Exhibit 101\n\n*\n\nThis certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n​\n\n​\n\n**\n\nCertain identified information in the exhibit has been omitted because it is the type of information that (i) the Company customarily and actually treats as private and confidential, and (ii) is not material.\n\n​\n\n​\n\n​\n\n​\n\n43\n\n[Table of Contents](#TOC)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\nCentury Therapeutics, Inc.\n\n​\n\n​\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Brent Pfeiffenberger, PharmD, MBA\n\n​\n\n​\n\nBrent Pfeiffenberger, PharmD, MBA\n\n​\n\n​\n\nChief Executive Officer\n\n​\n\n​\n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Douglas Carr, CPA\n\n​\n\n​\n\nDouglas Carr, CPA\n\n​\n\n​\n\nSenior Vice President, Finance\n\n​\n\n​\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n​\n\n​\n\n44"}